Skip to main content

Table 5 Intensities of the peaks for different categories of the tumor characteristics

From: Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study

  

M/z4276

M/z4292

M/z8129

M/z8941

 

n

Median intensity

(IQR)

Median intensity

(IQR)

Median intensity

(IQR)

Median intensity

(IQR)

TNM stage

     

   IIA

26

13.00

(1.79–83.10)

19.51

(8.07–54.23)

26.27

(23.48–30.07)

33.56

(24.09–50.43)

   IIB

10

4.97

(1.33–17.24)

11.44

(4.83–15.79)

25.44

(16.56–27.75)

30.49

(20.16–34.59)

   III

11

11.88

(4.89–24.69)

15.86

(9.88–22.87)

25.70

(15.68–26.54)

37.55

(25.26–47.29)

p-value*

47

.340

.211

.203

.473

p-trend#

47

.553

.368

.075

.667

Tumor size

     

   0.5–2 cm

18

10.24

(1.36–85.58)

18.44

(5.44–63.09)

26.53

(22.86–30.08)

30.48

(23.24–61.21)

   > 2 cm

29

11.88

(3.97–24.51)

12.21

(8.71–24.28)

25.90

(19.08–27.45)

32.90

(24.04–44.16)

p-value

47

.844

.526

.204

.896

Lymph node involvement

     

   No

9

24.34

(5.99–72.28)

25.69

(9.91–54.35)

26.48

(23.33–30.29)

38.92

(27.68–53.99)

   Yes

38

8.66

(1.87–24.37)

13.13

(5.97–23.74)

25.81

(18.87–27.65)

30.49

(23.30–43.31)

p-value

47

.137

.144

.224

.224

Differentiation

     

   High-Intermediate

25

11.04

(2.99–24.47)

14.06

(7.86–22.52)

25.72

(19.84–27.45)

31.27

(24.13–42.65)

   Low

21

19.90

(2.98–60.12)

17.06

(8.71–44.18)

26.54

(19.68–29.79)

28.99

(23.34–45.88)

p-value

46

.635

.384

.360

.903

  1. M/z = Mass to Charge ratio, IQR = Inter-Quartile Range, * Kruskal Wallis Test, # Jonckheere-Terpstra Test, Mann-Whitney U Test